Wedbush analyst Robert Driscoll started coverage of Replimune Group with an Outperform rating and a $24 price target. The stock was also added to Wedbush’s Best Ideas list given high conviction in its next-generation oncolytic virus platform, which is designed to synergize with immune checkpoint blockade. The analyst also sees a high likelihood of success for lead asset RP1, which is currently in a Phase 1/2 study with initial data in the second half of 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.